[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585465":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":11,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":11,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"oral tranexamic acid","EXPERIMENTAL",null,[13],"Drug: oral tranexamic acid",{"label":15,"type":16,"description":11,"interventionNames":17},"Oral Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","one group of subjects will receive oral tranexamic acid and the other will receive oral placebo",[9],{"type":21,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Placebo","one group of randomized subjects will receive placebo and the other will receive oral tranexamic acid",[15],[29],{"name":30,"affiliation":5,"role":31},"Walter Smith, MD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},"Walter Smith","CONTACT","205-930-8554","waltersmith@uabmc.edu",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Birmingham","Alabama","35205","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-86.80249,33.52066,{"lat":50,"lon":49},[53,54],{"name":34,"role":35,"phone":36,"phoneExt":11,"email":37},{"name":30,"role":31,"phone":11,"phoneExt":11,"email":11},{"type":31,"investigatorFullName":34,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Principal Investigator","100585465","phase-3-effects-of-oral-tranexamic-acid-on-short-term-postoperative-outcomes-following-total-shoulder-arthroplasty-100585465",false,"NCT06902714","Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty","Evaluating the Effects of Oral Tranexamic Acid on Short Term Postoperative Outcomes Following Total Shoulder Arthroplasty: A Randomized Control Trial","Inclusion Criteria:\n\n* Skeletally mature patients (ages 18-79) undergoing primary total shoulder arthroplasty\n\nExclusion Criteria:\n\n* Patients with Cancer, venous thromboembolism, stroke, heart disease, pregnant or nursing, allergic to TXA, current tobacco use, anticoagulants other than aspirin.","ALL","18 Years","79 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE3","The purpose of this clinical trial is to evaluate the short-term clinical outcomes of patients undergoing total shoulder arthroplasty who receive an extended postoperative course of oral tranexamic acid",[75],"Shoulder Arthroplasty","2026-04-22",{"date":78,"type":79},"2026-04-28","ACTUAL",{"date":81,"type":79},"2026-04-20",{"date":83,"type":69},"2030-12",{"name":5,"class":6},1]